

Are pulmonary fibrosis and Alzheimer's disease linked? Shared dysregulation of two miRNA species and downstream pathways accompany both disorders

DOI 10.1074/jbc.L117.000502

Debomoy K. Lahiri^{†§1}, Bryan Maloney[‡], and Nigel H. Greig[¶]

From the [†]Department of Psychiatry, Indiana Alzheimer Disease Center, Stark Neurosciences Research Institute, and [§]Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana 46202 and [¶]Translational Gerontology Branch, Intramural Research Program, NIA, National Institutes of Health, Baltimore, Maryland 21224

Edited by Xiao-Fan Wang

As neuroscientists, we were intrigued when Huang *et al.* (1) reported that miR101 can attenuate pulmonary fibrosis (PF)² through suppression of Wnt family member 5A (WNT5A). Accumulating evidence suggests that *prima facie* unrelated disorders in multiple fields of medicine share fundamental molecular pathways. For example, PF associates with cognitive impairment (2). It is reasonable to presume that such links would be due to hypoxia and general inflammation, but could there be a deeper connection? Both miR101 and miR27b expression levels were significantly reduced in more severe PF cases (1). These same miRNA are implicated and reduced (3, 4) in Alzheimer's disease (AD). Interestingly, while miR101 levels are reduced in late-stage AD brain samples, an miRNA associated with AD and Parkinson's disease, miR153, is not (5). Notably, miR27b regulates peroxisome proliferator-activated receptor γ (PPAR γ), and PPAR γ disruption is implicated in both AD and PF (3). Wnt signaling disruption is a well-known molecular feature of AD (6). That two miRNA species are both down-regulated *and* pathways they regulate are linked to specific pulmonary and neurological disorders is noteworthy. If we want to take a broader view of connection or divergence of progressive disorders, we also can consider that miRNAs usually have multiple mRNA targets. In addition to regulating Wnt signaling, miR101 regulates levels of the A β -precursor protein (APP) and,

by extension, its neurotoxic processing product, A β (4). APP, as such, has not been directly implicated in PF, but it would not be unreasonable to propose that disruption of miR101 would impact several vital signaling and expression pathways. Disruption of a fundamental, multiorgan-wide pathway such as Wnt or PPAR γ signaling could be a broad precursor to multiple disorders, with specificity to be determined by other interactions. This suggests the potential for developing a therapeutic strategy to utilize common dysregulation of specific miRNAs for disparate diseases.

Acknowledgments—We thank Drs. A. Saykin and M. Srinivasan for their advice.

References

- Huang, C., Xiao, X., Yang, Y., Mishra, A., Liang, Y., Zeng, X., Yang, X., Xu, D., Blackburn, M. R., Henke, C. A., and Liu, L. (2017) MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation. *J. Biol. Chem.* **292**, 16420–16439
- Bors, M., Tomic, R., Perlman, D. M., Kim, H. J., and Whelan, T. P. (2015) Cognitive function in idiopathic pulmonary fibrosis. *Chron. Respir. Dis.* **12**, 365–372
- Jennewein, C., von Knethen, A., Schmid, T., and Brüne, B. (2010) MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor γ (PPAR γ) mRNA destabilization. *J. Biol. Chem.* **285**, 11846–11853
- Long, J. M., and Lahiri, D. K. (2011) MicroRNA-101 downregulates Alzheimer's amyloid- β precursor protein levels in human cell cultures and is differentially expressed. *Biochem. Biophys. Res. Commun.* **404**, 889–895
- Long, J. M., Ray, B., and Lahiri, D. K. (2012) MicroRNA-153 physiologically inhibits expression of amyloid- β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. *J. Biol. Chem.* **287**, 31298–31310
- Inestrosa, N. C., and Varela-Nallar, L. (2014) Wnt signaling in the nervous system and in Alzheimer's disease. *J. Mol. Cell. Biol.* **6**, 64–74

This work was supported by National Institute on Aging, National Institutes of Health Grants 5R01AG051086-03, 1R41AG053117-01, and P30AG010133 and the Intramural Research Program. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

¹ To whom correspondence should be addressed: Indiana University School of Medicine, 320 West 15th St., Indianapolis, IN 46202. Tel.: 317-274-2706; Fax: 317-231-0203; E-mail: dlahiri@iupui.edu.

² The abbreviations used are: PF, pulmonary fibrosis; AD, Alzheimer's disease; PPAR γ , peroxisome proliferator-activated receptor γ ; APP, A β -precursor protein.